指南与共识特殊人群用药

基于模型模拟的儿童COVID-19氯喹剂量推荐

Chloroquine Dosing Recommendations for Pediatric COVID-19 Supported by Modeling and Simulation.
指南 / 共识 · Clin Pharmacol Ther · 2020-05-21

研究采用生理药代动力学(PBPK)模型模拟成人和儿童氯喹暴露,以成人COVID-19方案44 mg/kg总剂量为参照,依据AUC0-70h差异确定各年龄组最佳剂量,并提出年龄调整的累积剂量方案。

要点

  • 儿童按体重给药时暴露与成人不同,需年龄调整剂量。
  • 推荐总累积剂量:0-1月35 mg/kg,1-6月47 mg/kg,6月-12岁55 mg/kg,青少年及成人44 mg/kg。
  • 任何患者总剂量不超过3,300 mg。

核心结论

  • 研究支持对COVID-19儿童进行年龄调整的氯喹给药,以避免剂量不足或毒性。

研究设计与样本

  • 基于已建立的氯喹PBPK模型模拟成人和儿童暴露,并用已发表药代动力学数据验证。

主要发现

  • 相同体重剂量下,不同年龄儿童与成人药物暴露存在差异。
  • 依据AUC0-70h差异确定各年龄组最佳剂量,验证各年龄组总暴露在成人预测值5%以内。

关键数值与推荐

  • 推荐总累积剂量:0-1月35 mg/kg(氯喹碱基),1-6月47 mg/kg,6月-12岁55 mg/kg,青少年及成人44 mg/kg。
  • 任何患者总剂量不超过3,300 mg。

临床怎么用

  • 临床可参考年龄调整的氯喹累积剂量方案用于COVID-19儿童。
  • 在缺乏儿童临床试验数据时,可采用模型引导的剂量选择范式。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

As chloroquine (CHQ) is part of the Dutch Centre for Infectious Disease Control coronavirus disease 2019 (COVID-19) experimental treatment guideline, pediatric dosing guidelines are needed. Recent pediatric data suggest that existing World Health Organization (WHO) dosing guidelines for children with malaria are suboptimal. The aim of our study was to establish best-evidence to inform pediatric CHQ doses for children infected with COVID-19. A previously developed physiologically-based pharmacokinetic (PBPK) model for CHQ was used to simulate exposure in adults and children and verified against published pharmacokinetic data. The COVID-19 recommended adult dosage regimen of 44 mg/kg total was tested in adults and children to evaluate the extent of variation in exposure. Based on differences in area under the concentration-time curve from zero to 70 hours (AUC0-70h ) the optimal CHQ dose was determined in children of different ages compared with adults. Revised doses were re-introduced into the model to verify that overall CHQ exposure in each age band was within 5% of the predicted adult value. Simulations showed differences in drug exposure in children of different ages and adults when the same body-weight based dose is given. As such, we propose the following total cumulative doses: 35 mg/kg (CHQ base) for children 0-1 month, 47 mg/kg for 1-6 months, 55 mg/kg for 6 months-12 years, and 44 mg/kg for adolescents and adults, not to exceed 3,300 mg in any patient. Our study supports age-adjusted CHQ dosing in children with COVID-19 in order to avoid suboptimal or toxic doses. The knowledge-driven, model-informed dose selection paradigm can serve as a science-based alternative to recommend pediatric dosing when pediatric clinical trial data is absent.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Verscheijden LFM, van der Zanden TM, van Bussel LPM, et al. Chloroquine Dosing Recommendations for Pediatric COVID-19 Supported by Modeling and Simulation. Clin Pharmacol Ther. 2020. PMID: 32320477. doi:10.1002/cpt.1864

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。